Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online December 15, 2020.
Article Versions
- You are currently viewing a Latest version of this article (December 15, 2020 - 04:00).
- latest version (May 1, 2021 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2020 The Journal of Rheumatology
Author Information
- Elisabeth Mogard,
- Tor Olofsson,
- Stefan Bergman,
- Ann Bremander,
- Lars-Erik Kristensen,
- Jack Kvistgaard Olsen,
- Johan K. Wallman and
- Elisabet Lindqvist
- Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Skåne University Hospital, Department of Rheumatology, Lund, Sweden; Primary Health Care Unit, Department of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Spenshult Research and Development Centre, Halmstad, Sweden; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark; Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark; The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Frederiksberg and Bispebjerg, Copenhagen, Denmark.
Supported by grants from the Faculty of Medicine, at Lund University; Region Skåne; Skåne University Hospital; Spenshult Research and Development Centre; ALF Region Skåne; the Swedish Rheumatism Association; the Anna-Greta Crafoord Foundation; the Kock Foundation; the Österlund Foundation; and the Lundgren Foundation.
Conflict of interest: TO has received interview fees from Eli Lilly and provided consultancy for Merck, Sharp & Dohme (MSD) (unrelated to the present work). LEK has received consultancy and speaker’s bureau fees from AbbVie; Amgen; Biogen; Bristol-Myers Squibb (BMS); Celgene; Eli Lilly; Janssen Pharmaceuticals; Merck, Sharp & Dohme (MSD); Novartis; Pfizer; Roche; Sannofi; and UCB Pharma (unrelated to the present work). JKW has received consultancy fees from AbbVie; Celgene; Eli Lilly; Novartis; and UCB Pharma (unrelated to the present work). The remaining authors have no competing interests.
Corresponding author: Elisabeth Mogard, Department of Rheumatology, Skåne University Hospital, Kioskgatan 5, SE-221 85 Lund, Sweden. E-mail: elisabeth.mogard@med.lu.se.